Theranostics Market (2026-2036)

The global theranostics market is undergoing a paradigm shift, evolving from a niche nuclear medicine application to a mainstream pillar of precision oncology. This integrated approach, which combines targeted diagnostic imaging with personalized therapeutic intervention, is fundamentally changing the way chronic diseases, particularly cancer, are managed. By using the same targeting molecule for both detecting and treating a disease, theranostics allows for unprecedented precision, ensuring that the right treatment is delivered to the right patient at the right time. The market's robust growth is primarily fueled by the commercial success of radioligand therapies (RLTs), which have demonstrated superior clinical outcomes in late-stage cancers that were previously considered untreatable.

The commercial success of Novartis' Pluvicto for metastatic prostate cancer and Lutathera for neuroendocrine tumors has validated the theranostic model on a global scale. Oncology remains the dominant application area, accounting for approximately 85% of market revenue, driven by the growing global cancer burden and the increasing demand for highly targeted treatment approaches with improved efficacy and safety profiles. Global cancer incidence is projected to rise substantially over the coming decades, supporting continued adoption of theranostic solutions. Beyond oncology, theranostic approaches are being explored in cardiovascular and neurological disorders, creating opportunities for future growth through advanced molecular imaging and targeted therapeutic strategies. The integration of high-resolution PET/CT and SPECT/CT systems continues to strengthen the diagnostic component of theranostics by providing detailed molecular information that supports patient selection, treatment planning, and response monitoring.

Technological advancements remain a key driver of theranostics market growth, with increasing emphasis on Targeted Alpha Therapy (TAT). Alpha-emitting isotopes such as Actinium-225 (Ac-225) deliver highly localized, high-energy radiation and have demonstrated significant potential for targeting tumor cells while limiting radiation exposure to adjacent healthy tissues due to their short path length. As a result, TAT has attracted substantial investment from leading pharmaceutical companies, contributing to a wave of strategic acquisitions and partnerships across the radiopharmaceutical sector. In parallel, the development of nanotheranostics, which integrates targeted drug delivery with diagnostic imaging capabilities, is creating new opportunities for precision medicine and the development of personalized treatment strategies.

Geographically, North America is expected to remain the largest regional market, accounting for approximately 42% of global revenue in 2026. The region's leadership is supported by a strong research ecosystem, favorable regulatory pathways, established radiopharmacy networks, and advanced nuclear medicine infrastructure. Asia-Pacific is projected to register the fastest growth during the forecast period, driven by rising cancer incidence, expanding healthcare investments, and increasing deployment of cyclotron facilities and radiopharmaceutical manufacturing capabilities in countries such as China and India. As investments in isotope production infrastructure improve supply availability and clinical evidence continues to support the use of theranostic agents in earlier treatment settings, the market is expected to maintain strong double-digit growth through 2036.